Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (Note: Request metadata listed "ABVC BIOPHARMA, INC." but the filing identifies the registrant as American BriVision (Holding) Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Period: August 13, 2019 (Event Date: August 4, 2019)
The Company entered into a Material Definitive Agreement to convert outstanding debt owed to four related party investors into common stock.
Key Financial Metrics
This filing does not provide standard financial statements (Revenue, Profit, Cash Flow, Margins, or Liquidity ratios). The only specific financial data disclosed relates to the debt conversion transaction:
- Total Debt Converted: $625,591
- Shares Issued: 89,370 shares of common stock
- Conversion Price: $7.00 per share
- Market Context: The conversion price was below the closing price of the common stock on August 2, 2019.
Material Changes
The primary material change is the reduction of liabilities and increase in equity resulting from the conversion agreement:
- Liability Reduction: The Company is released from debts, liabilities, and obligations totaling $625,591 owed to the four investors.
- Equity Issuance: The Company issued 89,370 unregistered shares of common stock to the investors.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management discussion regarding future operations.
Regulatory Status: The issuance of shares was made in reliance on the exemption from registration pursuant to Section 4(a)(2) under the Securities Act of 1933.
Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the execution of the conversion agreement.
Investor Verification Checklist
- Verify the identity of the four related party investors and the nature of the original debt agreements.
- Confirm the exact closing price of the stock on August 2, 2019, to assess the discount of the $7.00 conversion price.
- Review the full text of the Conversion Agreement (Exhibit 10.1) for any covenants or conditions not summarized in the 8-K.
- Check subsequent filings to confirm the issuance of the 89,370 shares and the removal of the $625,591 liability from the balance sheet.